VC-backed Intellia Therapeutics appoints chief financial and strategy officer
Intellia Therapeutics, a developer of therapeutic products for gene editing and repair, has named Dr. Sapna Srivastava as chief financial and strategy officer. She is a former senior analyst and biotechnology group team leader at Goldman Sachs. Intellia Therapeutics is backed by Atlas Venture and Novartis Institutes for Biomedical Research.
22 April 2015•2 mins read
